Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BeiGene : Cancer Drug Brukinsa Meets Phase 3 Trial Goal

07/30/2021 | 06:15am EDT


© MT Newswires 2021
All news about BEIGENE, LTD.
09/17Asian ADRs Move Lower in Friday Trading
MT
09/17US Futures Modestly Lower Ahead of Fed Meeting Next Week
MT
09/17BEIGENE : Receives Positive Opinion for Brukinsa by European Medicines Agency; S..
MT
09/17Top Premarket Gainers
MT
09/17BEIGENE : Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Tr..
BU
09/17BeiGene Gets CHMP Backing of Brukinsa in Waldenstrom's Macroglobulinemia
DJ
09/16Health Care Stocks Largely Sitting Out Markets Recovery This Afternoon
MT
09/16Health Care Stocks Falling Thursday Afternoon
MT
09/16INSIDER SELL : Beigene
MT
09/16LEAP THERAPEUTICS : Says Additional Data from Mid-Stage Study Show Potential of ..
MT
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2021 1 255 M - -
Net income 2021 -1 110 M - -
Net cash 2021 3 429 M - -
P/E ratio 2021 -37,8x
Yield 2021 -
Capitalization 37 507 M 37 507 M -
EV / Sales 2021 27,2x
EV / Sales 2022 24,5x
Nbr of Employees 6 400
Free-Float 68,2%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 403,14 $
Average target price 402,32 $
Spread / Average Target -0,20%
EPS Revisions
Managers and Directors
John V. Oyler Chairman & Chief Executive Officer
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Jane E. Huang Chief Medical Officer-Hematology
Yong Ben Chief Medical Officer-Immuno & Oncology Department
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.56.02%37 507
BIONTECH SE340.60%90 003
GILEAD SCIENCES, INC.22.91%89 434
REGENERON PHARMACEUTICALS34.93%67 910
WUXI APPTEC CO., LTD.35.75%65 728
VERTEX PHARMACEUTICALS-20.33%48 539